title: [Evaluation of the immunity level achieved with the oral polio vaccine in schoolchildren aged 6 to 12 years of Catalonia (Spain)].
abstract: OBJECTIVE
  To evaluate the immunity level achieved with oral polio vaccine in schoolchildren aged 6-12 years of Catalonia (Spain).
  
  
  METHODS
  The prevalence of antibodies against poliovirus 1, 2 and 3 was investigated using the neutralizing technique in a representative (n = 197) sample of schoolchildren aged 6-12 years of Catalonia (Spain) obtained in 2001.
  
  
  RESULTS
  The prevalence of antibodies was 94.4% for poliovirus 1; 98.5% for poliovirus 2, y 73.1% for poliovirus 3. 93.4% of serum samples had antibodies against poliovirus 1 and 2; 70.6% against poliovirus 1 and 3, and 69.5% against poliovirus 1, 2 and 3. The prevalence of antibodies was similar in different socio-demographic groups. Schoolchildren who had been vaccinated (5 doses) had a higher level of antibodies against poliovirus 3 than those who had not completed vaccination (4 or less doses): 75.4% vs 50.0% (p < 0.05). The prevalence of antibodies against poliovirus 1 and 2 was similar in schoolchildren completing and not completing vaccination.
  
  
  CONCLUSIONS
  Results obtained in this study show that 26.9% of schoolchildren aged 6-12 years do not have an adequate immunity level against poliovirus 3 with the oral polio vaccine, being it necessary to develop an immunization program using the inactivated polio vaccine.
authors.affiliation: Direcció General de Salut Pública, Departament de Salut, Generalitat de Catalunya, Barcelona, España. pedro.plans@gencat.net
authors.forename: Pedro
authors.initials: P
authors.lastname: Plans Rubió
authors.forename: Núria
authors.initials: N
authors.lastname: Rabella García
authors.forename: Magdalena
authors.initials: M
authors.lastname: Otegui Zabalo
authors.forename: Jordi
authors.initials: J
authors.lastname: Espuñes Vendrell
authors.forename: Angela
authors.initials: A
authors.lastname: Domínguez García
authors.forename: Antoni
authors.initials: A
authors.lastname: Plasència Taradach
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D017955:Poliovirus / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000276:immunology*; D016036:Seroepidemiologic Studies; D013030:Spain
chemical_list: D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral